{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/hypercholesterolaemia-familial/how-up-to-date-is-this-topic/update/","result":{"pageContext":{"chapter":{"id":"4cd7461b-b74a-5b4a-bbf9-499684c190d6","slug":"update","fullItemName":"Update","depth":2,"htmlHeader":"<!-- begin field 6f731189-8fac-4a39-9579-f4c1a17d83c1 --><h2>Update</h2><!-- end field 6f731189-8fac-4a39-9579-f4c1a17d83c1 -->","summary":null,"htmlStringContent":"<!-- begin item 40fc9b84-736f-4db0-b0a5-777e916c88c4 --><!-- end item 40fc9b84-736f-4db0-b0a5-777e916c88c4 -->","topic":{"id":"e1e436f3-28ca-5b97-8fd7-0156f61bfd7c","topicId":"030641a4-5f0a-4edf-a3ac-c21903c0095e","topicName":"Hypercholesterolaemia - familial","slug":"hypercholesterolaemia-familial","lastRevised":"Last revised in September 2020","chapters":[{"id":"23ce1270-bfbc-5ded-ab6d-c230787a3f98","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"1ac01f09-287f-5fd1-a1a5-3392235af19a","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"a92fc8a9-1061-5c02-bfff-d5f934ffdb53","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"93e2888f-005e-50e1-8f04-9c8023c43019","slug":"changes","fullItemName":"Changes"},{"id":"4cd7461b-b74a-5b4a-bbf9-499684c190d6","slug":"update","fullItemName":"Update"}]},{"id":"ebac4860-8279-5daa-8053-2376a8a9d71d","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"18209ebb-2e72-5f12-879c-4cac6c4a4a74","slug":"goals","fullItemName":"Goals"},{"id":"db603b52-871f-5820-9fbc-8fa05bcd0c1c","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"107217fb-afa8-59f5-b492-20a089b4ff48","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"55a1140b-b028-5056-9c88-5836bc15dd3b","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"ef31a150-3669-5487-b7f5-e19d13bf639e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"00bd8dc2-4dee-5ba6-a759-82c99a58cd4d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"2cc20b8e-5159-51e2-b31b-9d3f16bcff36","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"ec5f41d9-1fa0-53f1-aaee-0b37d62682af","slug":"definition","fullItemName":"Definition"},{"id":"687776fd-3a40-5dcf-ada0-1e58ff0f3128","slug":"causes","fullItemName":"Causes"},{"id":"cb1847cd-3321-5104-a764-beaf8c58397c","slug":"prevalence","fullItemName":"Prevalence"},{"id":"63b1cca3-87f7-5577-af56-fb3b38977e30","slug":"complications-prognosis","fullItemName":"Complications and prognosis"}]},{"id":"13588941-b46f-5306-a752-0527c4458410","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"4be7f4e2-6458-5112-948b-50b0e98bbb7a","slug":"identification","fullItemName":"Identification"},{"id":"343de6bd-ed4d-5fcc-b7d7-7ca1565daf0d","slug":"assessment-diagnosis","fullItemName":"Assessment and diagnosis"}]},{"id":"13ac6594-5e56-502b-96f4-2f848eb59c83","fullItemName":"Management","slug":"management","subChapters":[{"id":"2349db0e-12d5-5ff8-8e14-2e885307ad42","slug":"adults-with-heterozygous-fh","fullItemName":"Scenario: Adults with heterozygous FH"},{"id":"2f9228e9-d4af-55d1-937d-74e9c83e418e","slug":"adults-with-homozygous-fh","fullItemName":"Scenario: Adults with homozygous FH"},{"id":"c8ba3d52-d1bc-5e22-a366-a32ab938db00","slug":"children-young-people-with-fh","fullItemName":"Scenario: Children and young people with FH"}]},{"id":"323963cd-05be-519c-a523-3922e41f11f0","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"9c555b9e-f39b-567f-89ff-c983ab785087","slug":"statins-atorvastatin-rosuvastatin-simvastatin","fullItemName":"Statins (atorvastatin, rosuvastatin, and simvastatin)"},{"id":"8007ba2c-d902-5e52-9fb3-1aedd9470650","slug":"ezetimibe","fullItemName":"Ezetimibe"}]},{"id":"189143bc-5ae2-58d6-83ae-e0cd9bc01ee6","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"efd82555-8ecb-5170-be69-2e7390295832","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"652a4e82-a231-5cb4-8c7c-563ca0f43bbf","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"2be02b62-6acf-5570-854e-e6dcbfb36426","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"7d6217e2-3ab0-516c-97eb-53f4083e8805","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"2ce56158-d459-5b28-8343-7b6d776dc77a","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"3f7dd940-f042-5f4d-8968-a8002af95e8d","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"ca7fcd28-909d-579e-8783-9249cd67764f","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"a92fc8a9-1061-5c02-bfff-d5f934ffdb53","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"ec28a533-e127-5496-8231-ec4df1b9ef45","slug":"new-evidence","fullItemName":"New evidence","depth":3,"htmlHeader":"<!-- begin field 2609d6d3-9662-472d-9b01-b219d392b1df --><h3>New evidence</h3><!-- end field 2609d6d3-9662-472d-9b01-b219d392b1df -->","summary":null,"htmlStringContent":"<!-- begin item f70deaa7-f519-4541-9a11-a1b03b70762f --><!-- begin field 07391c6f-4825-49b1-b314-b6e65b9b889c --><h3>Evidence-based guidelines</h3><!-- end field 07391c6f-4825-49b1-b314-b6e65b9b889c --><!-- begin field bedf6677-3d6c-497e-bca4-0cbf52a5d38c --><ul><li>NICE (2019) <em>Familial hypercholesterolaemia: identification and management.</em> National Institute for Health and Care Excellence. <a href=\"https://www.nice.org.uk/\" data-hyperlink-id=\"5399f714-66f6-43a7-a494-aae200c8c31e\">www.nice.org.uk</a> [<a href=\"https://www.nice.org.uk/guidance/cg71\" data-hyperlink-id=\"70ec7238-5430-4a5a-bb56-aae200c8c340\">Free Full-text</a>]</li></ul><!-- end field bedf6677-3d6c-497e-bca4-0cbf52a5d38c --><!-- begin field 6e170917-8d2a-4521-80e4-51217ecd8a82 --><h3>HTAs (Health Technology Assessments)</h3><!-- end field 6e170917-8d2a-4521-80e4-51217ecd8a82 --><!-- begin field 6d9a23a6-63ce-44d8-a7bb-c710c881cfd7 --><p>No new HTAs published since 1 February 2019.</p><!-- end field 6d9a23a6-63ce-44d8-a7bb-c710c881cfd7 --><!-- begin field c95b4b86-672c-4981-a145-e4f1612c8789 --><h3>Economic appraisals</h3><!-- end field c95b4b86-672c-4981-a145-e4f1612c8789 --><!-- begin field 0032a5d4-21ce-4110-86ce-cf0e19a527d5 --><p>No new economic appraisals relevant to England since 1 February 2019.</p><!-- end field 0032a5d4-21ce-4110-86ce-cf0e19a527d5 --><!-- begin field a6ea92fa-28d1-4fa9-9f02-cc2cd4dd6674 --><h3>Systematic reviews and meta-analyses</h3><!-- end field a6ea92fa-28d1-4fa9-9f02-cc2cd4dd6674 --><!-- begin field 3bc814d7-7dec-4a65-b5fb-ee22e7cb38ca --><ul><li>Adams, S.P., Alaeiilkhchi, N., Wright, J.M. (2020) <em>Pitavastatin for lowering lipids.</em> Cochrane Library. <a href=\"https://www.cochranelibrary.com/\" data-hyperlink-id=\"7ce0f91b-f9f8-49a0-a603-ac4100b30a53\">www.cochranelibrary.com</a> [<a href=\"https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012735.pub2/full\" data-hyperlink-id=\"d02eef53-43fa-4432-9869-ac4100b30b2d\">Free Full-text</a>]</li></ul><!-- end field 3bc814d7-7dec-4a65-b5fb-ee22e7cb38ca --><!-- begin field 1790cddb-2cf9-4f97-a9aa-c367d0f2d7d9 --><h3>Primary evidence</h3><!-- end field 1790cddb-2cf9-4f97-a9aa-c367d0f2d7d9 --><!-- begin field 0a35760a-ec9f-4e84-ad63-5d0c440c6dbd --><p>No new primary evidence published since 1 February 2019.</p><!-- end field 0a35760a-ec9f-4e84-ad63-5d0c440c6dbd --><!-- end item f70deaa7-f519-4541-9a11-a1b03b70762f -->","subChapters":[]},{"id":"996948cd-e022-53e6-9076-130f0a89c4cd","slug":"new-policies","fullItemName":"New policies","depth":3,"htmlHeader":"<!-- begin field 0484d648-6c6b-4fe5-b413-dd7764522191 --><h3>New policies</h3><!-- end field 0484d648-6c6b-4fe5-b413-dd7764522191 -->","summary":null,"htmlStringContent":"<!-- begin item 0eff907f-e76d-4262-99af-41a2ca91c9fa --><!-- begin field 27e191e1-5d06-4acb-ae18-b1294996ef6e --><p>No new national policies or guidelines since 1 February 2019.</p><!-- end field 27e191e1-5d06-4acb-ae18-b1294996ef6e --><!-- end item 0eff907f-e76d-4262-99af-41a2ca91c9fa -->","subChapters":[]},{"id":"6884327f-9058-5abb-adb4-4e9861e72cb9","slug":"new-safety-alerts","fullItemName":"New safety alerts","depth":3,"htmlHeader":"<!-- begin field 63b59209-1430-409d-9158-572747786a4e --><h3>New safety alerts</h3><!-- end field 63b59209-1430-409d-9158-572747786a4e -->","summary":null,"htmlStringContent":"<!-- begin item a78c55bb-9deb-4f16-99bb-e2477e284308 --><!-- begin field 95653057-fc0b-4b3d-9e94-6ec6e5d6fdc4 --><p>No new safety alerts published since 1 February 2019.</p><!-- end field 95653057-fc0b-4b3d-9e94-6ec6e5d6fdc4 --><!-- end item a78c55bb-9deb-4f16-99bb-e2477e284308 -->","subChapters":[]},{"id":"73446ceb-0a89-51d8-a8e4-cc6df7d953af","slug":"changes-in-product-availability","fullItemName":"Changes in product availability","depth":3,"htmlHeader":"<!-- begin field 343a65d6-c233-4c06-a2ea-d1e4b1323784 --><h3>Changes in product availability</h3><!-- end field 343a65d6-c233-4c06-a2ea-d1e4b1323784 -->","summary":null,"htmlStringContent":"<!-- begin item 78dbf0df-d2ca-4bbd-9eae-f76040889ca7 --><!-- begin field 11c6bfb5-eda2-4ac3-878a-b11b05a99f08 --><ul><li>Nilemdo is licensed for treatment of adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet, either as monotherapy or in combination with a statin. See more <a href=\"https://www.medicines.org.uk/emc/product/11743/smpc\" data-hyperlink-id=\"c3cdd2f3-484b-4293-b182-ac3300b4bb8b\">here</a>. </li><li>Nustendi is licensed for treatment of adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet, either as monotherapy or in combination with a statin. See more <a href=\"https://www.medicines.org.uk/emc/product/11744/smpc\" data-hyperlink-id=\"f3ca27fd-c1ed-4653-b907-ac3300d1e4b6\">here</a>.</li><li>Inclisiran is licensed for the treatment of adults with primary hypercholesterolemia (heterozygous familial and non-familial) or mixed dyslipidemia, as an adjunct to diet, either alone or in combination with a statin or statin with other lipid-lowering therapies. See more <a href=\"https://www.medicines.org.uk/emc/product/12039/smpc\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"a668048e-edc3-4dbc-ba11-acc600b8164b\">here</a>.</li></ul><!-- end field 11c6bfb5-eda2-4ac3-878a-b11b05a99f08 --><!-- end item 78dbf0df-d2ca-4bbd-9eae-f76040889ca7 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}